SHR7390 / Jiangsu Hengrui Pharma - LARVOL DELTA

SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (clinicaltrials.gov) - P2 | N=6 | Completed | Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting ➔ Completed | N=10 ➔ 6 | Trial completion date: Feb 2023 ➔ Jun 2023 | Trial primary completion date: Aug 2022 ➔ Jun 2023

Enrollment change • Metastases • Trial completion • Trial completion date • Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials. (PubMed, Oncologist) - "SHR7390 0.5 mg plus camrelizumab showed a manageable safety profile. Preliminary clinical activity was reported regardless of MSI and BRAF status."

Journal • Monotherapy • P1 data • Colorectal Cancer • Gastrointestinal Cancer • Immunology • Microsatellite Instability • Oncology • Solid Tumor • BRAF • MSI

SHR7390-I-102-AST: The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=31 | Terminated | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | N=60 ➔ 31 | Unknown status ➔ Terminated; Sponsor R & D Strategy Adjustment

Combination therapy • Enrollment change • Trial termination • Oncology • Solid Tumor • BRAF

[VIRTUAL] A phase I study of SHR7390 plus camrelizumab in advanced/metastatic colorectal cancer. (ASCO 2021) - P1 | "SHR7390 plus camrelizumab showed a tolerable safety profile . Preliminary clinical activity was reported regardless of BRAF and MSI status, and future studies are warranted to further evaluate these results."

IO biomarker • P1 data • Anemia • Colorectal Cancer • Gastrointestinal Cancer • Hematological Disorders • Immune Modulation • Immunology • Inflammation • Microsatellite Instability • Oncology • Solid Tumor • BRAF • MSI

SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (clinicaltrials.gov) - P2 | N=10 | Recruiting | Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Not yet recruiting ➔ Recruiting

Enrollment open • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

MULAN: Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer (clinicaltrials.gov) - P2; N=319; Recruiting; Sponsor: Fudan University; Not yet recruiting ➔ Recruiting; N=170 ➔ 319

Enrollment change • Enrollment open • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PGR

SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (clinicaltrials.gov) - P2; N=10; Not yet recruiting; Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Clinical • New P2 trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

MULAN: Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer (clinicaltrials.gov) - P2; N=170; Not yet recruiting; Sponsor: Fudan University

New P2 trial • Breast Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=60; Recruiting; Sponsor: Jiangsu HengRui Medicine Co., Ltd.; Trial completion date: Jul 2019 ➔ Dec 2019; Trial primary completion date: Dec 2018 ➔ Jul 2019

Clinical • Combination therapy • Trial completion date • Trial primary completion date

Phase I Study of SHR7390 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=60; Recruiting; Sponsor: Jiangsu HengRui Medicine Co., Ltd.; Trial primary completion date: Dec 2018 ➔ Apr 2019

Clinical • Trial primary completion date